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Summary 
Although the classical chemotactic receptor for complement anaphylatoxin C5a has been associated 
with polymorphonuclear and mononuclear phagocytes, several recent studies have indicated that 
this receptor is expressed on nonmyeloid  cells including human endothelial cells, vascular smooth 
muscle cells, bronchial  and alveolar epithelial cells, hepatocytes, and in the human hepatoma 
cell line HepG2. In this study, we examined the possibility that other members of the chemotactic 
receptor family are expressed  in HepG2 cells and human liver, and the possibility that such receptors 
mediate changes in acute phase gene expression in HepG2 cells. Using polymerase chain reaction 
(PCR) amplification of HepG2 mRNA with primers based on highly conserved regions of the 
chemotactic subgroup of the G protein-coupled receptor family, we identified a PCR fragment 
from the formyl-methionyl-leucyl-phenylalanine (FMLP) receptor, as well as one from the C5a 
receptor. Immunostaining with antipeptide  antisera to FMLPR confirmed the presence of this 
receptor  in  HepG2  cells. Receptor binding  studies  showed  specific saturable  binding  of a 
radioiodinated FMLP analogue to HepG2 cells (Ka •  2.47 nM; R ~  6  x  103 plasma membrane 
receptors per cell). In situ hybridization analysis showed the presence of FMLPIk mRNA in 
parenchymal cells of the human liver in vivo. Both C5a  and FMLP mediated concentration- 
and time-dependent changes in synthesis of acute phase proteins in HepG2 cells induding increases 
in complement C3, factor B, and otl-antichymotrypsin, as well as concomitant decreases  in albumin 
and transferrin  synthesis. The effects of CSa and FMLP on the synthesis of these acute phase 
proteins was evident at concentrations  as low as 1 nM, and they were specifically blocked by 
antipeptide  antisera for the corresponding receptor. In contrast to the effect of other mediators 
of hepatic acute phase gene regulation,  such as interleukin 6, the effects of C5a and FMLP were 
reversed by increased concentrations  well above the saturation point of the respective receptor. 
These results suggest that acute phase gene regulation by CSa and FMLP is desensitized at high 
concentrations, a property that is unique among the several  known mechanisms for hepatic acute 
phase gene regulation. 
T 
he complement C5a fragment and the synthetic N-formyl 
peptide  FMLP are best known as prototype activators 
of neutrophils  and neutrophil chemotactic activity. C5a is 
a 11,200-D cationic glycopeptide that is derived from the first 
74 amino acid residues of the amino terminus of the C5 oe 
chain (1, 2). It is generated by the action of the classical com- 
plement pathway (C4b,  2a,3b) or alternative complement 
pathway (C3b, Bb, P) convertases during complement activa- 
tion (3-5).  C5a has been shown to mediate chemotactic ac- 
tivity,  phagocytic  activity,  release of active oxygen inter- 
mediates,  release of  granular  enzymes,  and  increase  in 
adhesion/aggregation properties in neutrophils  (reviewed in 
6-8). C5a is also thought to have vasoactive  properties, medi- 
ating vasodilatation (9), increased vascular permeability (10), 
smooth muscle contraction (11), and release  of histamine from 
mast cells (12). FMLP is one of several N-formyl tripeptides 
originally discovered by Schiffmann et al. (13) as the active 
principle  in  supernatants  of bacterial  cultures  that  were 
chemotactic for mammalian phagocytes in vitro.  FMLP is 
now known to activate a complex program in neutrophils 
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gen intermediates, and release of proteolytic and phlogistic 
granular contents (reviewed  in 14). 
It has been known for some time that the effects of CSa 
and FMLP are mediated by distinct specific receptor-activated 
signal transduction pathways. In each case, signal transduction 
is associated with cellular calcium mobilization, is regulated 
by homologous desensitization, and is inhibited by pertussis 
toxin, providing evidence that members of the G protein-cou- 
pled receptor family are involved. Sequence analyses of cDNAs 
for high affinity CSa (15, 16) and FMLP (17) receptors  have 
shown by structural criteria that these receptors do indeed 
belong in the G protein-coupled receptor family. In fact, the 
structures of the C5a and FMLP receptors have been shown 
to be highly conserved in a subfamily of G protein-coupled 
receptors that include the IL-8A, IL-SB, C-C chemokine, and 
MIP-lot receptors  (18, 19). In addition to seven transmem- 
brahe-spanning domains that are relatively conserved among 
the entire G protein-coupled receptor family, the so-called 
"chemokine" receptor subfamily is highly conserved in the 
sequence of the first, second, third, sixth, and seventh mem- 
brane-spanning domains and has a highly conserved stretch 
of nine amino acids on the cytoplasmic loop just after the 
third transmembrane domain. This receptor subfamily is also 
related by pharmacological characteristics,  as well as func- 
tional involvement in chemotaxis and inflammatory activation. 
Although CSaK and FMLPK expression has been associated 
with cells of myeloid origin, such as neutrophils, eosinophils, 
monocytes, macrophages, and myeloid cell lines U937 and 
HL-60, several recent studies have suggested that C5aR is 
expressed in nonmyeloid cells. Foreman et al. (20) have shown 
that C5a binds to human endothelial cells. We have shown 
that C5aR is expressed in vascular smooth muscle cells, en- 
dothelial cells, bronchial and alveolar  epithelial cells of the 
lung, as well as in parenchymal cells of the liver and human 
hepatoma HepG2 cells  (21). C5aR  expression  in vascular 
smooth muscle cells and endothelial cells could be respon- 
sible for the vasoactive properties of C5a, but there are no 
previous data that would provide an explanation for the func- 
tion of C5aR in bronchoalveolar epithelial cells and hepato- 
cytes. In this study, we used HepG2 mRNA in PCK with 
primers based on highly conserved regions of the chemotactic 
G protein-coupled receptor subfamily to examine the possi- 
bility that other members of the subfamily are expressed in 
liver cells. We also examined the possibility that expression 
of C5aK and/or other chemotactic receptors in liver cells was 
functionally significant by determining whether ligands for 
these receptors  could elicit acute phase gene expression  in 
HepG2 cells, a model system reflecting the acute inflamma- 
tory response of liver. 
Materials and Methods 
PCR of Chemotactic Receptors, Subclonin~ and Sequencing.  Total 
cellular KNA was isolated from HepG2 cells  by guanidine isothio- 
cyanate  extraction/cesium chloride centrifugation/ethanol precipi- 
tation (22) and poly(A) KNA was prepared by oligo (dT)-cellulose 
column chromatography. Double-stranded cDNA was synthesized 
using a kit from Amersham Corp. (Arlington Heights, IL). Addi- 
tion ofBstXI nonpalindromic linkers to the blunt-end cDNA and 
size fractionation of cDNA on a 1% agarose gel were performed 
using a kit from InVitrogen (San Diego, CA). cDNA larger than 
1.0 kb was recovered from the gel and ligated to BstXI-digested 
CDM8 vector (23). Esckerichia coli MC1061/p3 cells were trans- 
formed with the ligated DNA using the InVitrogen kit. The com- 
pleted library represented '~4  x  10  s recombinants. Plasmid DNA 
was isolated from an amplified aliquot of the transformed library 
using a kit from QIAGEN Inc. (Chatsworth, CA). This plasmid 
DNA was used as template for PCK. Several sets of degenerate 
oligonucleotides  were used in the PCK: one primer pair was based 
on highly conserved regions in the second and sixth transmem- 
brane domains of the tachykinin G protein-coupled receptors (24, 
25)  (MII  sense: CTIGCIT/cTIGCIGAT/cT/c~  MVI  antisense: 
GGGIAGCCAGCAGAIC/cWAT/cWAAA);  a second primer pair 
was based on highly conserved  regions in the third and sixth trans- 
membrane domains of the tachykinin G protein-coupled receptors 
(24, 25) (Mill sense: CTGTGC/TGC/TC/GATT/cGCIITG/TGAT/c 
A/cGC/oTAC; MVI antisense: exactly as delineated above); a third 
primer pair was based on highly conserved regions in the second 
and seventh transmembrane domains of the chemotactic G pro- 
tein-coupled  receptors, including II~8RA, IL-8KB,  C5aK, FMLPK, 
C-C  CKK  K  (18) (M2CC  sense: T/cTIAAT/cT/c  TIG- 
CIT/~CTIGCIGAT/cT/cT; M7CC antisense: TGICCIC/AT/cIA- 
c/^IG/ACG/ATAIAT/cAIATIGGC/AT);  a fourth set was identical 
to the set used  by Neote et al. (18) to clone C-C chemokine  receptors 
from U937 cells [M2CC G sense: CTG/cAACC/TTGGCC/GT/o 
TG/^GCC/TGACC/TTA/cCTC; M7CCG antisense: TGGCCG/c 
A/GT/cG/cA^/cG/cA/cCG/ATAGAT/GG/cAIGC~GTT; DKYCCG 
antisense: GC^/c TGGACA/GATNGCNAGG  TANCGA/GTC]. 
PCK conditions  were 55 cycles  at 92~  for 1 min, 50-55  ~ for 1 min, 
and 70~  for 2 rain. PCK products were subcloned  in the pGEM3z 
plasmid (Promega Corp., Madison, WI) and plasmid DNA was 
subjected to sequencing  with the Sequenase  kit (U.S. Biochemicals 
Corp., Cleveland, OH). 
In Situ Hybridization Analysis.  Human liver was obtained from 
two different organ donors through the Mid America Transplant 
Association (St. Louis, MO). The studies were approved by the 
Human Studies Committee of Washington University School of 
Medicine. In a protocol that has been previously described (26), 
cryostat sections (5-8 #m) of liver were fixed in 4% paraformalde- 
hyde and prehybridized after proteinase K digestion (1 #g/ml for 
10 rain). Hybridization with 3sS-UTP-labeled antisense cRNA 
probe was performed at 55~  for 24 h in 60% formamide, 15% 
dextran sulfate, lx  Denhardt's solution, 1 mM EDTA, 10 mM 
Tris HC1, pH 8, 400 mM NaC1. Sections were then subjected to 
RNAse A digestion to remove all nonhybridized single-stranded 
KNA, washed at stringencies up to 0.1x SSC at SS~  for 30 rain, 
and exposed to photoemulsion for 26 d at 4~  Cellular expression 
of mKNA was indicated by the presence of silver grains. To be 
certain that the hybridization signals were specific, sequential sec- 
tions of the same tissue were hybridized under identical conditions 
using 3sS-UTP-labeled sense probe. 
Flow Cytometry.  Flow cytometric analysis was conducted as 
follows: 4  x  10  s HepG2 cells were removed  from flasks  using PBS 
with 5 mM EDTA. Cells were washed twice in 0.1% BSA-PBS 
supplemented with 1 mM CaC12 and 0.05% NAN3, dispersed into 
15-ml conical tubes, and incubated with 5 #1 of the anti-FMLPR 
antiserum on ice for 30-45 min. Cells were kept on ice so as to 
minimize downmodulation of FMLPR caused by receptor inter- 
nalization. Cells were washed three times in cold buffer and in- 
cubated in the dark for 30 rain with FITC-goat anti-rabbit IgG 
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in 1% paraformaldehyde, and rapidly resuspended in 200 #1 of  buffer 
for analysis. Controls received irrelevant primary antibody (preim- 
mune serum) or second antibody alone. 
Immunofluorescence Studies.  HepG2 cells were seeded onto glass 
coverslips, cultured for 3 d, rinsed with PBS, and then permeabi- 
lized with acetone for 1 min at room temperature. Cells were then 
incubated with rabbit anti-human FMLPR antiserum or preim- 
mune rabbit serum in PBS with 3% BSA for 2 h at room tempera- 
ture. Coverslips were washed three times in PBS, 1% Triton X-100, 
0.2% Tween 20 and then incubated for 1 h at room temperature 
in the dark with FITC-anti-rabbit IgG. The coverslips were then 
washed three times and mounted on glass slides for microscopic 
viewing. 
Receptor-binding Assays.  The FMLP analogue formylNLe-Leu- 
Phe-NLe-Tyr-Lys was obtained from Sigma Immunochemicals (St. 
Louis, MO) and was labeled with Na 125I using chloramine T ex- 
actly as described in previous studies (27). 12SI-FMLP  analogue was 
separated from free 12sI by Sephadex G-10 (Pharmacia,  Piscataway, 
NJ) gel filtration. Specific radioactivity was •2,000-6,000  cpm/ng 
of  peptide. Monolayers of HepG2 cells were washed vigorously with 
PBS and then incubated for 2 h at 4~  in binding medium (DMEM, 
10 mM Hepes, pH 7.2,  1 mg/ml BSA,  0.05%  Tween 80) with 
125I-FMLP analogue in several different concentrations. Duplicate 
samples were incubated in the absence (total binding) or presence 
(nonspecific binding) of a 200-fold molar excess unlabeled FMLP. 
After the 2-h incubation at 4~  the cells were washed with PBS 
and then solubilized in 1 N  NaOH for gamma counting. Specific 
binding  was  determined  by  the  difference between  total  and 
nonspecific binding. 
Regulation of Acute Phase Protein Biosynthesis.  Monolayers of 
HepG2 cells were rinsed and then incubated at 37~  for different 
time intervals in serum-free DMEM alone or supplemented with 
FMLP or recombinant human C5a (Sigma) in different concentra- 
tions. At the end of  each of these incubations, the monolayers were 
again rinsed and incubated at 37~  for 30 min in the presence of 
methionine-free medium containing 250 #Ci/ml [35S]methionine. 
Cells  were  then  solubilized  and  cell  lysates  were  subjected  to 
clarification. Cell lysates were also subjected to TCA precipitation 
to determine relative total protein synthesis according to previously 
described protocols (28).  Aliquots of cell lysates were incubated 
overnight at 4~  in 1% Triton X-100,  1.0% SDS, 0.5% deoxy- 
cholic acid, with excess antibody. Immune complexes  were then 
precipitated with excess formalin-fixed staphylococci-bearing pro- 
tein A (Immunoprecipitin; Life Technologies,  Inc., Gaithersburg, 
MD), washed, released by boiling in Laemmli sample buffer, and 
applied to SDS-PAGE under reducing conditions. Gels were dried 
for fluorography as previously described (28). A laser densitometer 
(model 2222 Ultrascan XL; LKB Instruments, Inc., Houston, TX) 
was used for scanning of fluorograms. 
Antibodies.  Synthetic peptides with sequences that corresponded 
to divergent regions of  the amino-terminal  extracellular tails of  C5aR 
(C5aR  7-24:  TTPDYGHYDDKDTLDLTN)  and  of  FMLPR 
(FMLPR 4-21: NSSLPTNISGGTPAVSAG) were coupled to KLH. 
The KLH-coupled peptides were used as immunogens to raise an- 
tipeptide antisera in rabbits. By ELISA, anti-C5AR and anti-FMLP 
antisera were specific, sensitive, and were shown to specifically in- 
hibit immunofluorescent staining of  dbcAMP-stimulated  U937 cells 
by C5a  and FMLP. 
Results 
Identification of FMLPR  Expression  in  HepG2  Cells.  In 
previous studies, we discovered C5aR expression in HepG2 
Figure  1.  PCR  amplification of G protein-coupled  receptors from 
HepG2 cells. Total RNA was isolated from HepG2 cells and subjected 
to PCR as described in Materials and Methods. (Lane I) Primers for 
amplification of oel-antitrypsin cDNA.  (Lane 2) No template. (Lane 3) 
5' primer for the second transmembrane domain of the chemotactic G 
protein-coupled  receptors (M2CC) and 3' primer for the sixth transmem- 
brahe domain of the tachykinin  G protein-coupled receptors  (MV/). (Lane 
4) 5' primer for the third transmembrane  domain of the tachykinin  G pro- 
tein--coupled receptors (Mill) and 3' primer for the seventh transmem- 
brane domain of the chemotactic G protein-coupled receptors (M7CC). 
(Lane 5) 5' primer for the second  transmembrane  domain of  the tachykinin 
G protein-coupled receptors (MII) and 3' primer of MTCC. (Lane 6) 5' 
primer of M2CC and 3' primer of M7CC. The relative  migration of  DNA 
markers and of the 780-bp fragment corresponding to FMLPR are indi- 
cated at the right  margin. 
cells and human liver parenchymal cells in vivo (21). To de- 
termine whether other members of the chemotactic G pro- 
tein-coupled receptor family are expressed in HepG2 ceils, 
we subjected plasmid DNA from an HepG2 cDNA library 
to PCR with primers based on highly conserved regions of 
the  tachykinin  G  protein-coupled  receptor family and  the 
subgroup of chemotactic G  protein-coupled receptors (Fig. 
1).  A  single PCR fragment of 1,400 bp was generated with 
positive control primers based on otl-antitrypsin (oel-AT) 1 se- 
quence  (lane  1).  PCR  fragments  were not  detected in  the 
absence  of template  (lane  2).  Multiple  PCR  fragments  of 
"o200-1,600 bp  were generated with primers based on the 
tachykinin G protein-coupled receptors (lanes 3-5). A  single 
PCR product of ,o780 bp was detected with primers based 
on the chemotactic G protein-coupled receptors (lane 6). This 
product was subjected to DNA sequence analysis and found 
to be identical to the human FMLPR sequence (17). We did 
not  detect  separate  PCR  products  for  any  of  the  other 
chemotactic receptors.  Using  another pair of primers iden- 
tical to the ones that  were used to detect C5aR,  IL-8AR, 
IL-8BR,  and C-C chemokine R  in U937 cells by Neote et 
al.  (18), we detected a PCR fragment that was identical to 
C5aR.  Even with  this  last pair of primers,  however, there 
was  no evidence for IL-8AR,  IL-8BR., or C-C chemokine 
R  in  HepG2  ceils  (data  not  shown). 
Next, we examined the possibility that FMLPR could be 
detected by immunofluorescence at the cell surface of HepG2. 
HepG2 cells were incubated with anti-FMLPR peptide anti- 
serum,  anti-C5aR peptide antiserum,  or preimmune serum 
1 Abbreviations  used in this  paper: ACT, antichymotrypsin; AT, antitrypsin. 
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Figure 2.  Flow cytometry of 
HepG2 cells. HepG2 cells were in- 
cubated  with  anti-FMLPR  an- 
tiserum  (solid line,  at-FMLPR), 
anti-C5aR antiserum (dotted line, 
ot-C5a-R), and preimmune serum 
(dashed  line,  GAR-FITC),  and 
then analyzed by flow cytometry 
as  described  in  Materials  and 
Methods. 
and then incubated with FITC-conjugated anti-Ig for flow 
cytometric analysis (Fig. 2). The results showed a significant 
shift for anti-FMLPR and by anti-C5aR staining, but not 
for preimmune serum or  anti-IL-8AR  staining (data not 
shown). 
To determine whether FMLPR is functionally active in 
these cells  and  to provide quantitative characterization of 
FMLPR expression, HepG2 cells were subjected to receptor- 
binding assays with a radioiodinated FMLP analogue (Fig. 
3).  These studies demonstrated the presence of specific and 
saturable binding  of t2sI FMLP  analogue to  HepG2  cells 
(Fig. 3 A). Scatchard plot analysis of these binding data predicts 
a Kd of ",2.47 nM and ",,6,000 plasma membrane receptors 
per cell (Fig.  3 A).  Competitive binding assays show that 
recognition of radioiodinated FMLP analogue by HepG2 cells 
is specific (Fig. 3 B): it is inhibited by FMLP in a concentra- 
tion-dependent manner, but is not inhibited by C5a in concen- 
trations that inhibit binding of 12sI-CSa to HepG2 cells (21), 
and is not inhibited by peptide 105Y in concentrations that 
inhibit binding of 125I-peptide 105Y  to HepG2 cells (27). 
To exclude the possibility that FMLPR expression in HepG2 
cells is a result of transformation of liver cells into a con- 
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Figure 3.  Specific binding of 
12SI-FMLP analogue  to  HepG2 
cells.  (A) HepG2 cells were in- 
cubated for 2 h at 4~  with con- 
centrations  of  t2SI-FMLP  ana- 
logue shown on the horizontal 
axis in the absence (total) or pres- 
ence  (nonspecific)  of  250-fold 
molar excess of unlabeled FMLP. 
The difference between total and 
nonspecific binding is designated 
specific binding. The results  are 
reported as cell-associated  radio- 
activity on the vertical axis. The 
inset shows the Scatchard plot of 
the specific 12SI-FMLP analogue 
binding. (B) Percent inhibition of 
binding of 12SI-FMLP analogue 
(5 nM) to HepG2 by FMLP, CSa, 
and peptide 105Y. Fold molar ex- 
cess competitor is shown at the 
bottom of each bar.  Results are 
reported as mean  _+  1 SD. 
210  FMLP and C5a Receptor in Liver Cells Figure  4.  In situ  hybridization  of human liver tissue.  (~p) A section  of human liver probed  with an antisense 3sS-UTP-labeled-FMLPR  cRNA 
as described in Materials  and Methods (x 200). Background  signal was determined  by incubating  an adjacent section  of human liver with sense 3sS- 
UTP-labeled FMLPR cRNA (bottom). tinuous cell line and not necessarily a reflection of the physi- 
ological function of hepatocytes in vivo, we examined by in 
situ hybridization analysis the possibility that FMLPR is ex- 
pressed  in liver cells in vivo.  Sections of human liver  were 
subjected to in situ hybridization with 3sS-UTP-labeled  an- 
tisense FMLPR cRNA (Fig.  4).  The results show localiza- 
tion of silver grains to parenchymal cells throughout the liver 
lobule (Fig. 4, top). This hybridization is specific for FMLPR 
mRNA as demonstrated by the absence  of silver grains in 
serial sections incubated with 3sS-UTP-labeled sense FMLPR 
cR.NA (Fig. 4, bottom).  These data provide further evidence 
that FMLPR is expressed  in liver cells. 
Effect of C5a and FMLP on Acute Phase Protein Biosynthesis 
in HepG2 Cells.  Because CSa and FMLP play a role in the 
inflammatory  response of myeloid cells, we examined the pos- 
sibility  that  the  interaction  of these  peptides  with  their 
receptors  on HepG2 cells induces a hepatic inflammatory re- 
sponse.  Many previous  studies have  shown that a hepatic 
inflammatory response,  or what is now called the "hepatic 
acute phase response,"  can be elicited in the HepG2 cell line 
(reviewed  in 29, 30).  First, we examined the effect of C5a 
and FMLP on synthesis of a prototype positive acute phase 
reactant, C3 (Fig. 5). C3 expression is upregulated by several 
different acute phase cytokines including IL-1,  TNF,  and 
IFN-% HepG2 cells were incubated at 37~  for 10 h in serum- 
free medium or supplemented with C5a, FMLP, or as posi- 
tive control, a combination of IL-1B and IL-6. Cells  were 
then subjected to labeling with [3SS]methionine for analysis 
of the synthesis of specific proteins. The results show that 
both C5a and FMLP mediate increases in C3 synthesis (Fig. 
5, left). The effects of C5a and FMLP on C3 synthesis were 
evident at concentrations as low as I nM and were less than 
but comparable in magnitude to the combined effect of IL-I~ 
and IL-6. The effects were specific in that both C5a and FMLP 
mediated concentration-dependent decreases in synthesis of 
albumin, a prototype negative acute phase reactant, in the 
same cell monolayers (Fig.  5,  right).  The effect of CSa on 
albumin biosynthesis was first evident at 10 nM, whereas that 
of FMLP was evident at 1 nM. In each case, the magnitude 
of the effect was less than but comparable to that of the com- 
bination of IL-1B and IL-6. There was some variation in the 
magnitude of the effect of C5a and FMLP on synthesis of 
C3 and albumin from one experiment to the next. Results 
of at least  five different experiments are  shown in Table  1 
to show the magnitude variation in terms of standard devi- 
ations. 
Next, we examined the time dependence of the effect of 
C5a and FMLP on synthesis of C3 and albumin. Separate 
monolayers of HepG2 cells were incubated for time intervals 
of up to 24 h with serum-flee medium alone or supplemented 
with C5a or FMLP and then subjected to analysis for syn- 
thesis  of C3 and albumin. Results for time intervals of up 
to 6 h are shown in Fig. 6. The results show that the effects 
of C5a and FMLP, including increase  in C3 synthesis and 
decrease  in albumin synthesis, are time dependent and be- 
come evident as early as 6  h  after addition. 
We also examined the effect of C5a and FMLP on a number 
Figure 5.  Effect  of C5a and FMLP  on synthesis  of C3 and albumin 
in HepG2 cells. Separate monolayers  of HepG2 cells were incubated at 
37~  for 10 h in serum-flee  medium  or medium  supplemented  with C5a 
(1 and 10 mM), FMLP  (1 and 10 riM) or, as positive  control, a combina- 
tion of IL-1/~  (10 ng/ml) and Ib6 (10 ng/ml). Calls were then subjected 
to labeling  with [3sS]methionine  for 30 min. Separate  aliquots of the same 
cell lysates  were subjected  to immunoprecipitation  with anti-C3 and anti- 
albumin for analysis  by SDS-PAGE next to molecular  mass markers as in- 
dicated at the right margin.  There  were no significant  differences  in total 
TCA-precipitable radioactivity  between monolayers. 
of other acute phase proteins. For these experiments, HepG2 
cells were incubated for 6 h with C5a or FMLP and then 
subjected  to  labeling  with  [3SS]methionine.  Radiolabeled 
cells were lysed, and separate aliquots of the same cell lysates 
were subjected to immunoprecipitation with different anti- 
bodies (Fig.  7).  Acute phase proteins that are regulated by 
several different cytokines were initially selected for analysis. 
The results show that C5a and FMLP have similar effects, 
mediating increases in synthesis of C3, complement Bf, and 
proteinase inhibitor O~l-antichymotrypsin  (o~I-ACT). In the 
same experimental material, C5a and FMLP mediated decreases 
in synthesis of albumin and transferrin, but had no effect on 
olvAT or C5. Several other acute phase proteins were exam- 
ined. Synthesis of positive acute phase proteins fibrogen and 
C4 was minimally and inconsistently increased by C5a and 
Table  1.  Effect  of CSa and FMLP on Net Synthesis of 
Plasma Proteins in HepG2  Cells 
Percent change from control* 
Plasma protein  N*  CSa  s  FMLP  s 
C3  6  349  -+  69  370  +_  74 
Albumin  5  52  _+  21  46  _+  24 
* Number of separate experiments. 
$  Mean +  SD as determined  by densitometric  scanning. 
S  5 nM; 6-h incubation. 
212  FMLP  and C5a Receptor in Liver Cells Figure 6.  Time required for C5a and FMLP to mediate changes in syn- 
thesis of C3 and albumin (ALB)  in HepG2 cells. Separate monolayers of 
HepG2 cells were incubated at 37~  for 3 or 6 h in serum-free medium 
or medium supplemented with CSa (10 nM) or FMLP (10 nM). Synthesis 
of C3 (left) and albumin (right) was then analyzed exactly as described in 
the legend for Fig. 5. 
Figure 7.  Effect  of C5a and FMLP 
on synthesis  of several  acute phase pro- 
teins in HepG2 cells. Separate mono- 
layers of HepG2 cells were incubated 
at  37~  for  6  h  with  serum-free 
medium (0), medium supplemented 
with C5a at  1 and 10 nM (left),  or 
medium supplemented with FMLP at 
I and 10 nM (right). Synthesis  of  acute 
phase proteins was then analyzed ex- 
actly as described  in the legend for Fig. 
5, except that antibodies to C3, Bf, 
c~I-ACT, ~I-AT, albumin, transferrin, 
and C5 were used for immunoprecip- 
itation of separate aliquots of the same 
radiolabeled cell lysates. 
Figure 8.  (A) Effect  of  FMLP on synthesis  of C3 and albumin  in HepG2 
cells: blocking by anti-FMLPR and anti-C5aR antisera. Separate monola~rs 
of HepG2 cells  were incubated at 37~  for 6 h in serum-free  control medium 
(lane 1), medium supplemented with FMLP (5 nM; lane 2), or medium 
supplemented with FMLP (5 nM) + either anti-CSaR antiserum (at dilu- 
tions of 1:100 [lane 3] or 1:20 [lane 4]) or anti-FMLPR antiserum (at dilu- 
tions of 1:100 [lane 5] or 1:20 [lane 6]). Synthesis of C3 and albumin  was 
then analyzed exactly as described in the legend for Fig. 5. (B) Effect of 
FMLP and C5a on synthesis  of  C3 in HepG2 cells:  blocking by anti-FMLPR 
and anti-C5aR antiserum. HepG2 cells were incubated at 37~  for 6 h 
in serum-free  control medium, medium supplemented with FMLP (5 nM), 
medium supplemented with FMLP (5 nM) +  either anti-CSaK  antiserum 
(1:100 and 1:20 dilutions)  or anti-FMLPK (1:100 and 1:20 dilutions), 
medium supplemented with CSa (5 riM), medium supplemented with CSa 
(5 nM) +  either anti-CSaR antiserum (1:100 and 1:20 dilutions) or anti- 
FMLPR (1:100  and 1:20 dilutions), medium supplemented with anti-C5a 
antiserum (1:20  dilution) alone or medium supplemented with anti-FMLPR 
antiserum (1:20 dilution) alone. C3 synthesis was analyzed by the method 
described in the legend for Fig. 5, but here the radiolabeled polypeptide 
corresponding  to pro-C3  on the fluorograms was subjected to densito- 
metric scanning. Results are reported on the horizontal axis as fold-increase 
over control with mean _+  1.0 SD when three or more separate experi- 
ments were available. 
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tion of serum amyloid A  or C-reactive protein  synthesis in 
HepG2 cells that had been incubated with C5a or FMLP (data 
not  shown). 
Next,  we examined the capacity for antibodies to C5aR 
and FMLPR to inhibit the effects of C5a and FMLP on acute 
phase  synthesis  in  HepG2  cells.  Synthetic  peptides  corre- 
sponding to divergent regions in the amino-terminal extracel- 
lular domains of C5aR and FMLPR were coupled to KLH 
and used to raise anti-C5aR and anti-FMLPR antisera. Sepa- 
rate monolayers of HepG2 cells were incubated for 6  h  in 
serum-free  control  medium,  medium  supplemented  with 
FMLP, or medium supplemented with FMLP and either anti- 
C5aR antiserum or anti-FMLPR antiserum. These monolayers 
were then  analyzed for  synthesis of C3  and  albumin  (Fig. 
8 A).  The results show that  FMLP mediates an increase in 
C3 synthesis. This increase is not blocked by anti-C5aR, but 
is  blocked  in  a  concentration-dependent  manner  by anti- 
FMLPR antiserum. FMLP also mediates a decrease in albumin 
synthesis that  is not blocked by anti-C5aR,  but is blocked 
in  a concentration-dependent  manner  by anti-FMLPR  an- 
tiserum.  In other  experiments  summarized  in Fig.  8 B we 
found that  the effect of C5a  on  C3  synthesis was blocked 
by anti-C5aR but not by anti-FMLPR. Anti-C5aR and anti- 
FMLPR antisera did not independently affect C3 synthesis. 
Taken together, these data indicate that the effect of C5a and 
FMLP on acute phase synthesis in HepG2 cells is mediated 
by C5aR  and  FMLPR,  respectively. 
Finally,  we examined the effect of very high concentrations 
of chemotactic peptides on synthesis of acute phase proteins 
in HepG2 cells.  Previous studies of neutrophils,  particularly 
neutrophil  chemotactic activity, have shown desensitization 
to chemotactic peptides as the neutrophils are exposed to in- 
creasing concentrations, concentrations well above the point 
at which receptor is saturated (14). For this experiment (Fig. 
9), HepG2 cells were incubated for 6 h in serum-free medium, 
medium supplemented with FMLP in several different con- 
centrations, or medium supplemented with a prototype acute 
phase cytokine IL-6 in several different concentrations. Again, 
acute phase protein  synthesis was assayed.  In  this case,  we 
examined c~i-ACT synthesis.  The results  show that  FMLP 
mediates a concentration-dependent  increase in oil-ACT syn- 
thesis up to an FMLP concentration  of 20 nM.  At higher 
FMLP concentrations,  ot~-ACT  synthesis returns to control 
levels (Fig.  9, le~).  In other experiments, there was also evi- 
dence for dissipation  of the effect of both  FMLP and C5a 
on C3  and  albumin  synthesis at the higher  concentrations 
of the  chemotactic  peptides  (data  not  shown).  IL-6  also 
mediates an increase in otl-ACT synthesis (Fig.  9, right).  Be- 
cause this experiment was started at very high concentrations 
of IL-6 (0.2/zg/ml) by design, one does not observe the con- 
centration dependence of the increase.  Previous studies have 
shown that  the effect of IL-6 on o~I-ACT  synthesis is con- 
centration  dependent at lower doses (29).  Most important, 
however, this result shows that once the IL-6 reaches its max- 
imal effect (0.2/xg/ml),  there is a plateau,  even up to 100- 
fold higher concentrations (20/zg/ml).  Taken together, these 
results  suggest  that  there is desensitization  of the effect of 
Figure 9.  Effect  of supersaturating concentrations of FMLP and ILo6 
on ~I-ACT synthesis  in HepG2  cells. Separate  monolayers  of HepG2  cells 
were incubated  at 37~  for 6 h in serum-free  control medium (0), medium 
supplemented with FMLP in several different concentrations (le~), or 
medium supplemented  with IL-6  in several  different  concentrations  (right). 
cd-ACT synthesis  was analyzed  exactly  as described  in the legend  for Fig. 5. 
chemotactic  peptides  at  supersaturating  concentrations  in 
HepG2 cells and show that there is a difference in the phar- 
macologic characteristics  of hepatic  acute phase regulation 
by chemotactic peptides as compared to the prototype acute 
phase  cytokines. 
Discussion 
The results of these studies  show that  liver ceUs express 
two members of the chemotactic G protein-coupled receptor 
family,  or chemokine receptor family.  In a previous study, 
we demonstrated  C5a expression in human  hepatoma cells 
and in human  liver parenchyma  in  situ (21).  Here, we de- 
tected FMLPR. expression in HepG2 and human liver paren- 
chymal cells using extremely sensitive assay systems such as 
PCR and in situ hybridization  analysis.  Expression of these 
two members of the chemotactic G protein-coupled receptor 
family in liver cells is specific  in that  there is no apparent 
expression of other members of this family in HepG2 cells. 
The primer used for PCR of HepG2 mRNA in this study 
induded a pair that have amplified,  from U937 cells, IL-8RA, 
IL-8RB, C-C CKR, orphan receptor HUMSTR, and CMV 
US 28 (18).  Another pair of primers would be expected to 
amplify several other tissue-specific orphan receptors (32-35). 
On the basis of this specificity,  we examined the possibility 
that  C5aR and FMLPR. play a role in the function of liver 
cells. Immunofluorescence analysis showed that both receptors 
are  expressed  on  the  surface of HepG2 cells  (Fig.  2),  and 
radioligand-binding assays showed that these receptors recog- 
nize their ligand with characteristics  similar to those origi- 
nally described in cells of myeloid lineage (Fig.  3).  Finally, 
each of these receptors activates a signal transduction pathway 
214  FMLP  and C5a Receptor in Liver Cells for regulation of acute phase protein biosynthesis in HepG2 
cells  (Figs.  5-9). 
During the host response to inflammation/tissue injury, 
there is a highly coordinated series of changes in intermediate 
metabolism with fever, muscle proteolysis, lipolysis, leukocy- 
tosis,  and marked changes in concentrations of plasma gly- 
coproteins termed acute phase plasma proteins.  Concentra- 
tions of several plasma proteins increase profoundly (C-reactive 
protein,  serum  amyloid  A),  others  increase  moderately 
(fibrinogen, Otl-AT, otl-ACT, complement proteins factor B 
and C3), and other plasma proteins decrease (albumin, trans- 
ferrin). Because these acute-phase plasma proteins are pre- 
dominantly derived from the liver, this part of the host re- 
sponse to inflammation/injury has been called the hepatic 
acute phase response. In recent years, it has become possible 
to identify several specific cytokines that are produced by local 
tissue and circulating mononuclear cells in response to pro- 
totype inflammatory stimuli, and that can elicit the diverse 
biological effects characteristic of the acute phase response. 
It has also become possible to demonstrate the effects of these 
cytokines on hepatic acute phase genes in tissue culture using 
several well-characterized hepatoma cell lines as well as pri- 
mary cell culture systems (reviewed in 29).  Each of these 
cytokines, including IL-6, IL-I~, IL-lc~, TNF-c~, leukemia 
inhibitory factor (LIF),  oncostain M,  and IL-11,  mediates 
changes in expression of at least several if not many acute 
phase genes in cell lines such as HepG2 (36-41).  The effect 
of each of these cytokines is also distinguished by mediating 
increases in the expression of "positive" acute phase reactants 
such as c~I-ACT, factor B, C3, and serum amyloid A at the 
same time as mediating decreases in expression of "negative" 
acute phase reactants such as albumin, prealbumin, and trans- 
ferrin. Data reported in this study show that CSa and FMLP 
have effects that are similar to these acute phase cytokines. 
Each mediates, through its receptor, concentration- and time- 
dependent increases in acute phase reactants such as C3, factor 
B, and oil-ACT, and decreases in negative acute phase reac- 
tants such as albumin and transferrin. 
The effects of C5a and FMLP are not as extensive as those 
of IL-6, which affect a number of additional acute proteins, 
including C-reactive protein, serum amyloid A, c~l-acid gly- 
coprotein, otrAT, fibrinogen, and others. Moreover, targeted 
disruption of the IL-6 gene severely impairs the hepatic acute- 
phase response elicited in vivo by turpentine (42). Thus, dis- 
ruption of the IL-6 gene provides evidence for the primacy 
of IL-6 in mediating the physiologic hepatic acute phase gene 
expression. In the IL-6 knockout mouse, however, some of 
the hepatic acute phase response to  turpentine is retained 
and the response to endotoxin is only reduced by '~50-60, 
raising the possibility that other mediators such as IL-1, TNF, 
LIF, oncostatin M, IL-11, and C5a play a significant role in 
the physiologic acute phase response in vivo. 
In contrast to the effect of cytokines such as IL-6, IL-1, 
and TNF, the effect of C5a and FMLP on acute phase pro- 
tein synthesis in HepG2 cells is abrogated at supersaturating 
concentrations. The effects of C5a and FMLP on neutrophil 
chemotaxis are also abrogated at supersaturating concentra- 
tions, a phenomenon that has been attributed to desensitiza- 
tion of the CSaR and FMLPR. Desensitization presumably 
permits the neutrophil to stop migrating as it reaches its des- 
tination. It is more difficult to conceptualize an explanation 
for desensitization of the hepatic acute phase response. This 
mechanism presumably provides for the termination of the 
hepatic acute phase response or at least the portion of the 
response that is elicited by complement fragments or bac- 
terial peptides. 
Although these studies show that FMLPR is expressed by 
liver cells and is capable of regulating acute phase protein 
biosynthesis,  the studies do not provide any information about 
what  ligand FMLPR  recognizes in vivo.  There are many 
reports of bacterial translocation across the intestine and into 
the portal vein which raise the possibility that bacterial pep- 
tides could in fact reach FMLPR on liver parenchymal cells. 
A recent study by Gao et al. (43) has shown that acetylated 
FMLP  analogues as well as nonacetylated, nonformylated 
FMLP analogues may be recognized by FMLPR.  This last 
study has, therefore, provided evidence for the possible exis- 
tence of other endogenous mammalian ligands. 
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